|
[이데일리 김보영 기자] AstraZeneca, a British pharmaceutical company, announced that it has discovered a’winning formula’ that can maximize the efficacy of the Corona 19 vaccine.
According to AFP news reports on the 27th, Pascal Sorio AstraZeneca, CEO of AstraZeneca, said in an interview with the Sunday Times that the company’s vaccine has a “100% protection” effect on the severe corona19.
CEO Sorio said, “As a result of the clinical trial, two injections showed similar efficacy of the vaccine to other competitors. This data will be released at some point in the future.”
Among the pharmaceutical companies that previously announced the results of phase 3 clinical trials, the Pfizer-Bioentech vaccine is known to be 95% effective and the Modena vaccine is 94.5% effective.
AstraZeneca’s vaccine showed an average of 70% lower efficacy than other vaccines in the initial phase 3 analysis. However, it was criticized for lowering reliability as it showed 90% efficacy when the dosage was changed to half the level.
Accordingly, AstraZeneca announced that it will revised and resumed the clinical trial to find the maximum efficacy by varying the dosage.
The UK Daily Telegraph said the vaccine, which was jointly developed by researchers at AstraZeneca and Oxford University, is expected to be approved by the UK Medicines and Health Care Products Authority (MHRA) on the 28th.
Unlike Pfizer or Modena vaccines that use mRNA technology, AstraZeneca’s vaccine plays a role in helping to form antibodies by inserting the mRNA code into a weaker version of the chimpanzee virus.
AstraZeneca said it could produce 200 million doses of vaccine worldwide by the end of the year, and more than 700 million doses by the end of March next year.